AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21355814 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg once daily
Number of subjects: 890
Study 21355814 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg once daily
Number of subjects: 890
Study 21355814 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine extended release 4 mg
Number of subjects: 890
Study 21355814 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 890
Study 19954554 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐PDR measured on day 1 in patients recovering spontaneously
Number of subjects: 25
Study 19954554 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐PDR measured on day 1 in patients not recovering spontaneously
Number of subjects: 25
Study 19954554 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG‐PDR value <= 6.3%/min on study day 1
Number of subjects: 25
Study 17685714 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and muscular strength training program (12 weeks)
Number of subjects: 32
Study 17685714 — intervention group
Group type: COMPARATOR
Intervention: Control group (dance-only approach)
Number of subjects: 32
Study 15119879 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite
Number of subjects: 27
Study 15119879 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically cured resin composite
Number of subjects: 27
Study 11317662 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAFA diet)
Number of subjects: 162
Study 11317662 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid diet (MUFA diet)
Number of subjects: 162
Study 11317662 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAFA diet) with low fat intake (< 37E%)
Number of subjects: 162
Study 11317662 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid diet (MUFA diet) with low fat intake (< 37E%)
Number of subjects: 162
Study 9036909 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program in acute medical care of the elderly
Number of subjects: 0
Study 7932162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (30 mg i.v.)
Number of subjects: 8
Study 2894547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 38
Study 2894547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 29629852 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice a day
Number of subjects: 44
Study 29629852 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice a day plus zidovudine and lamivudine
Number of subjects: 44
Study 29658256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Daozhuo Granules (BDG) at 200 ml bid for 4 weeks
Number of subjects: 478
Study 29658256 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd for 4 weeks
Number of subjects: 478
Study 26548691 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed material intervention
Number of subjects: 373
Study 26548691 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study 23959207 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced walking intervention (WI): 3 sessions per week for 4 weeks on a predetermined variable topographic course.
Number of subjects: 22
Study 23959207 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG): 30-minute stationary cycling, 3 sessions per week for 4 weeks.
Number of subjects: 22
Study 21150167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 67
Study 21150167 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 67
Study 18191683 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 18686
Study 16613209 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 16613209 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional corticosteroids
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional steroids
Number of subjects: 0
Study 12895211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 0
Study 11118461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a)
Number of subjects: 131
Study 11118461 — intervention group
Group type: COMPARATOR
Intervention: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a) with continuous infusion of fluorouracil (FU)
Number of subjects: 131
Study 11118461 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 131
Study 9167507 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 59
Study 7507638 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 120 or 240 mg/day
Number of subjects: 31
Study 7507638 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 or 200 mg/day
Number of subjects: 31
Study 7507638 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 10 or 20 mg/day
Number of subjects: 31
Study 7507638 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 50 or 100 mg/day
Number of subjects: 31
Study 7507638 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem and metoprolol in patients with >= 5 VPCs/hour at baseline
Number of subjects: 31
Study 2924990 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0
Study 2924990 — intervention group
Group type: COMPARATOR
Intervention: Parenteral pethidine
Number of subjects: 0
Study 1092284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate combined with chlordiazepoxide hydrochloride
Number of subjects: 0
Study 1092284 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide hydrochloride
Number of subjects: 0
Study 1092284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30903540 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental theory intervention (n=456)
Number of subjects: 867
Study 30903540 — intervention group
Group type: COMPARATOR
Intervention: Educational control intervention (n=411)
Number of subjects: 867
Study 28340446 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss interventions
Number of subjects: 409
Study 25419871 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker home visits (mean of 4.9 visits over 1 year)
Number of subjects: 366
Study 25419871 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 366
Study 24021043 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin 1000 kU three times a day via gastric tube
Number of subjects: 124
Study 24021043 — intervention group
Group type: COMPARATOR
Intervention: Gastrointestinal prokinetic drug (placebo)
Number of subjects: 124
Study 21741344 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for at least 3 years
Number of subjects: 219
Study 19466986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg (once daily for 7 days) + Diclofenac 50 mg (three times daily for 7 days)
Number of subjects: 0
Study 19466986 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 30 mg (once daily for 7 days)
Number of subjects: 0
Study 19466986 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg (once daily for 7 days) + Ibuprofen 800 mg (three times daily for 7 days)
Number of subjects: 0
Study 19442346 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 70
Study 19442346 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 70
Study 15257094 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective p38 MAP kinase inhibitor drug, RWJ‐67657 (single oral dose administered 30 min before endotoxin infusion)
Number of subjects: 21
Study 15257094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single oral dose administered 30 min before endotoxin infusion)
Number of subjects: 21
Study 11140429 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC MDI (1000 microg)
Number of subjects: 12
Study 11140429 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA MDI (1000 microg)
Number of subjects: 12
Study 11140429 — intervention group
Group type: COMPARATOR
Intervention: Intravenous FP (250 microg)
Number of subjects: 12
Study 7696060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal anaesthesia with i.v. fentanyl, propofol, atracurium and nitrous oxide
Number of subjects: 82
Study 7696060 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal anaesthesia
Number of subjects: 82
Study 2200555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 176
Study 2200555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 2200555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (for women in stage III)
Number of subjects: 176
Study 2200555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for women in stage III)
Number of subjects: 176
Study 2200555 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (for women after 2.5 years)
Number of subjects: 176
Study 2200555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for women after 2.5 years)
Number of subjects: 176
Study 7012398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 100
Study 7012398 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 30167752 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB with posterior capsule injection (PCI)
Number of subjects: 42
Study 30167752 — intervention group
Group type: COMPARATOR
Intervention: FNB only
Number of subjects: 42
Study 28388890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 ml, 1000 ml, 500 ml, or 250 ml bottle sizes of cola
Number of subjects: 37
Study 26044113 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in PANSS total scores during a three-month period
Number of subjects: 0
Study 26044113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-point reductions in PANSS total score during three months
Number of subjects: 0
Study 26044113 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of PANSS total score reduction for a year
Number of subjects: 0
Study 26044113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-point reduction in PANSS total score
Number of subjects: 0
Study 23996417 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaning with sodium hypochlorite wipes
Number of subjects: 59
Study 21371993 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based pharmacist care (e-BP)
Number of subjects: 9298
Study 21371993 — intervention group
Group type: COMPARATOR
Intervention: Lack of computer access
Number of subjects: 9298
Study 21371993 — intervention group
Group type: COMPARATOR
Intervention: Willingness to participate in the intervention
Number of subjects: 9298
Study 21371993 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for uncontrolled BP among participants with computer access
Number of subjects: 9298
Study 19393087 — intervention group
Group type: EXPERIMENTAL
Intervention: iFOBt with a faeces collection paper
Number of subjects: 10000
Study 19393087 — intervention group
Group type: COMPARATOR
Intervention: iFOBt without a collection paper
Number of subjects: 10000
Study 19393087 — intervention group
Group type: EXPERIMENTAL
Intervention: iFOBt (both groups)
Number of subjects: 10000
Study 18694250 — intervention group
Group type: EXPERIMENTAL
Intervention: BostonBreathes (BB) system - an interactive website for patient education, monitoring, and clinical teamwork.
Number of subjects: 0
Study 15126974 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate with film dressing
Number of subjects: 40
Study 15126974 — intervention group
Group type: COMPARATOR
Intervention: Paraffin gauze
Number of subjects: 40
Study 15126974 — intervention group
Group type: COMPARATOR
Intervention: Alginate alone
Number of subjects: 40
Study 15126974 — intervention group
Group type: COMPARATOR
Intervention: Film alone
Number of subjects: 40
Study 11228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes cryopreserved with cumuli partially removed mechanically
Number of subjects: 0
Study 11228204 — intervention group
Group type: COMPARATOR
Intervention: Oocytes cryopreserved with cumuli totally removed enzymatically
Number of subjects: 0
Study 11228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes cryopreserved with sucrose concentration of 0.2 mol/l
Number of subjects: 0
Study 11228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes cryopreserved with sucrose concentration of 0.3 mol/l
Number of subjects: 0
Study 11228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Oocytes with longer exposure time to cryoprotectants (15 min)
Number of subjects: 0
Study 11228204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) of thawed oocytes
Number of subjects: 0
Study 9492971 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic blood transfusions to reduce sickle hemoglobin to 30% or less
Number of subjects: 120
Study 9492971 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study 9895043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.i.d. for 3 days
Number of subjects: 19
Study 9895043 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 19
Study 9895043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 19
Study 9895043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2527376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (n = 13)
Number of subjects: 24
Study 2527376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (n = 8)
Number of subjects: 24
Study 2527376 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 3)
Number of subjects: 24
Study 2527376 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 24
Study 2527376 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 24
Study 2527376 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic disorder patients (n = 24)
Number of subjects: 24
Study 12915 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine with nortriptyline
Number of subjects: 0
Study 12915 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 0
Study 31567027 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward-Facing Child Restraint System (FFCRS)
Number of subjects: 72
Study 31567027 — intervention group
Group type: COMPARATOR
Intervention: Belt-Positioning Booster Seat (BS)
Number of subjects: 72
Study 31567027 — intervention group
Group type: EXPERIMENTAL
Intervention: Correctly restrained children
Number of subjects: 72
Study 31567027 — intervention group
Group type: COMPARATOR
Intervention: Incorrectly restrained children
Number of subjects: 72
Study 31567027 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall child occupant behavior
Number of subjects: 72
Study 28843988 — intervention group
Group type: EXPERIMENTAL
Intervention: Amagugu intervention
Number of subjects: 464
Study 28843988 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care
Number of subjects: 464
Study 26038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medications after acute myocardial infarction
Number of subjects: 7425
Study 26038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up appointments made before discharge
Number of subjects: 7425
Study 26038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider explained potential side effects of medications
Number of subjects: 7425
Study 26038524 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower medication adherence
Number of subjects: 7425
Study 23625188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg/day with 100 mg mirabegron OCAS
Number of subjects: 0
Study 23625188 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg/day with 100 mg mirabegron OCAS
Number of subjects: 0
Study 23625188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 160 mg immediate release in poor metabolizers
Number of subjects: 0
Study 23625188 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 and 100 mg OCAS in different CYP2D6 phenotypes
Number of subjects: 0
Study 21802745 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient group (N=16)
Number of subjects: 33
Study 21802745 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=17)
Number of subjects: 33
Study 19824412 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM) group (n=10)
Number of subjects: 20
Study 19824412 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (Control group, n=10)
Number of subjects: 20
Study 17112810 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole plus 20 mg famotidine (full-concomitant regimen)
Number of subjects: 15
Study 17112810 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole alone
Number of subjects: 15
Study 17112810 — intervention group
Group type: COMPARATOR
Intervention: 20 mg famotidine alone
Number of subjects: 15
Study 15701218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.4% ophthalmic solution
Number of subjects: 25
Study 15701218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11298850 — intervention group
Group type: EXPERIMENTAL
Intervention: Special intervention programme including dietary recommendations, weight loss instructions, self-monitoring of blood glucose for diabetics, smoking cessation programme, and follow-up visits every 6 months.
Number of subjects: 164
Study 11298850 — intervention group
Group type: COMPARATOR
Intervention: Usual care group with advice to quit smoking and lower fat and glucose consumption, similar antihypertensive treatment as intervention group.
Number of subjects: 164
Study 9290464 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone
Number of subjects: 30
Study 9290464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-ibopamine
Number of subjects: 8
Study 8100627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-ibopamine
Number of subjects: 8
Study 8100627 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker plus placebo
Number of subjects: 8
Study 3535100 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40
Study 3535100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 40
Study 3535100 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoclopramide and cimetidine
Number of subjects: 40
Study 3535100 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 29773463 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm system treatment for 16 weeks (Group B)
Number of subjects: 455
Study 29773463 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm system treatment for 20 weeks (Group C)
Number of subjects: 455
Study 29773463 — intervention group
Group type: COMPARATOR
Intervention: Alarm system treatment for 12 weeks (Group A)
Number of subjects: 455
Study 27777127 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Medication Complete Communication (EMC2) Strategy
Number of subjects: 1200
Study 27777127 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1200
Study 24434748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine-synthetic fiber socks
Number of subjects: 17
Study 24434748 — intervention group
Group type: COMPARATOR
Intervention: Cotton socks
Number of subjects: 17
Study 22834123 — intervention group
Group type: EXPERIMENTAL
Intervention: Polychemotherapy with cycloferon (111 patients)
Number of subjects: 238
Study 22834123 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy only (95 patients)
Number of subjects: 238
Study 19476474 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 2.5 mg
Number of subjects: 47
Study 19476474 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 47
Study 19476474 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 10 mg
Number of subjects: 47
Study 19476474 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study 19476474 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 47
Study 17590219 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD-7 depression metric
Number of subjects: 0
Study 17590219 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 17590219 — intervention group
Group type: COMPARATOR
Intervention: Comparison to tertiary sample
Number of subjects: 0
Study 15045033 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-ibritumomab tiuxetan (0.4 mCi/kg)
Number of subjects: 227
Study 15045033 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y-ibritumomab tiuxetan (0.3 mCi/kg)
Number of subjects: 227
Study 15045033 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 227
Study 11472705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg)
Number of subjects: 3916
Study 11472705 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (10 mg)
Number of subjects: 3916
Study 11472705 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin (20 mg)
Number of subjects: 3916
Study 11472705 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin (20 mg)
Number of subjects: 3916